Experienced in Polymyositis

Rik Joos

ZNA Jan Palfijn
Antwerpen, VLG, BE 
Experienced in Polymyositis
ZNA Jan Palfijn
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Rik Joos practices in Antwerpen, Belgium. Mr. Joos is rated as an Experienced expert by MediFind in the treatment of Polymyositis. His top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Arthritis, Axial Spondyloarthritis (AxSpA), and Juvenile Dermatomyositis.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Polymyositis.

Gender
Male

Locations

ZNA Jan Palfijn
Antwerpen, VLG, Belgium
Other Locations
Gent, VLG, Belgium
UZ Leuven, Vlaams Brabant
Leuven, VLG, Belgium
ZNA Jan Palfijn
Merksem, VLG, Belgium
Ziekenhuis Netwerk Antwerpen
Berchem, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial
Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Etanercept, Leflunomide
Study Phase: Phase 4
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
Enrollment Status: Completed
Publish Date: June 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Enrollment Status: Completed
Publish Date: September 27, 2019
Intervention Type: Other
View 5 Less Clinical Trials

41 Total Publications

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.
Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.
Journal: BMC rheumatology
Published: February 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Joos's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile